{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:20:38Z","timestamp":1783405238737,"version":"3.54.6"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glofitamab is a bispecific antibody (BsAb), and has good efficacy in relapsed or refractory B-cell non-Hodgkin lymphoma (r\/r B-NHL), especially in relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL). This study explored its sequential treatment\u2002strategies and efficacy in the real world, including rescue therapy after chimeric antigen receptor T cell (CAR-T) therapy failure, bridging CAR-T therapy and monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-center retrospective cohort analysis of 24 patients with clearly diagnosed relapsed\/refractory B-cell lymphoma, including primary diffuse large B-cell lymphoma (DLBCL), diffuse large B-cell lymphoma with Richter transformation (DLBCL-RT), and Burkitt lymphoma (BL). Patients were divided into three groups according to the treatment sequence: Group 1 (Glofitamab rescue therapy after progression of CAR-T therapy), group 2 (Glofitamab bridging subsequent CAR-T therapy), and group 3 (Glofitamab monotherapy), who received Glofitamab at our center between September 2024 and December 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the single-center real-world experience, Glofitamab demonstrated controllable safety and durable anti-tumor activity in three clinical scenarios. Especially, it could still bring clinical benefits even after CAR-T therapy failed, and it explored the sequential treatment strategy of Glofitamab and CAR-T.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1885982","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:45:48Z","timestamp":1783403148000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Glofitamab in the sequential treatment of relapsed\/refractory B-Cell lymphoma: a single-center real-world study"],"prefix":"10.3389","volume":"16","author":[{"given":"Haoran","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangce","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Clinical Research Ward of Cancer Center, Shanghai Tongji Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenbo","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xiu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Clinical Research Ward of Cancer Center, Shanghai Tongji Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aibin","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Clinical Research Ward of Cancer Center, Shanghai Tongji Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Clinical Research Ward of Cancer Center, Shanghai Tongji Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010005","article-title":"Epidemiology of non-hodgkin\u2019s lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large b-cell lymphoma: r-chop failure\u2014what to do","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematologyhematology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11899-025-00765-y","article-title":"The evolving therapeutic landscape of richter transformation","volume":"20","author":"Le","year":"2025","journal-title":"Curr Hematol Malig Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01274-4","article-title":"Richter's transformation","volume":"24","author":"Sigmund","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17203372","article-title":"Novel molecular insights and evolution of less toxic therapeutic strategies in burkitt lymphoma","volume":"17","author":"Lap","year":"2025","journal-title":"Cancers"},{"key":"B7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11912-020-0898-8","article-title":"Burkitt and burkitt-like lymphomas: a systematic review","volume":"22","author":"Saleh","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"114203","DOI":"10.1016\/j.isci.2025.114203","article-title":"Advances in the clinical application of bispecific antibodies in cancer therapy","volume":"28","author":"Zhou","year":"2025","journal-title":"Iscience"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016925","article-title":"Molecular features of response and resistance to glofitamab, a t-cell engager for treatment of large b-cell lymphoma","author":"Schmeing","year":"2026","journal-title":"Blood Advancesblood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"Cd20-tcb with obinutuzumab pretreatment as next-generation treatment of hematologic Malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Researchclinical Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large b-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (gemox) versus rituximab-gemox for relapsed or refractory diffuse large b-cell lymphoma (starglo): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1635589","article-title":"Glofitamab treatment of richter transformation with isolated central nervous system involvement: a case report","volume":"16","author":"Lu","year":"2025","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023419","article-title":"Car t cells vs bispecific antibody as third- or later-line large b-cell lymphoma therapy: a meta-analysis","volume":"144","author":"Kim","year":"2024","journal-title":"Bloodblood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-4504","article-title":"Real-world safety and mortality outcomes of car-t cell therapies versus bispecific antibodies in dlbcl: insights from the faers database","volume":"146","author":"Temiz","year":"2025","journal-title":"Bloodblood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5923","article-title":"Glofitamab for patients with non\u2013large b-cell lymphoma refractory or relapsing after anti-cd19 car t-cell therapy: final bicar study (lysa) results","volume":"146","author":"Cartron","year":"2025","journal-title":"Bloodblood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-7259","article-title":"Short-course glofitamab enables effective bridging to car-t therapy in b-nhl","volume":"146","author":"Liu","year":"2025","journal-title":"Bloodblood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3744","article-title":"Glofitamab in combination with cd19 car-t therapy for high-risk relapsed\/refractory large b-cell lymphoma","volume":"146","author":"Shen","year":"2025","journal-title":"Bloodblood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-7256","article-title":"Glofitamab based combined therapy as bridging therapy before stem cell transplants and car-t therapy in large b-cell lymphoma","volume":"146","author":"Wang","year":"2025","journal-title":"Bloodblood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-1952","article-title":"Early administration of cd20 x cd3 bispecific antibodies 4-6 weeks after car-t infusion for patients with residual or progressive large b cell lymphomas","volume":"146","author":"Chong","year":"2025","journal-title":"Bloodblood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00318-7","article-title":"Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis","volume":"13","author":"Sorin","year":"2026","journal-title":"Lancet Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"Astct consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2014.01.017","article-title":"Increasing the biological activity of il-2 and il-15 through complexing with anti-il-2 mabs and il-15r\u03b1-fc chimera","volume":"159","author":"Votavova","year":"2014","journal-title":"Immunol Lett"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2026.120115","article-title":"The role of cytokines in cytokine release syndrome (crs) after car t cell therapy","volume":"1873","author":"Gabriel","year":"2026","journal-title":"Biochim Et Biophys Acta (Bba)  Mol Cell Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41408-024-01119-2","article-title":"Chimeric antigen receptor t-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management","volume":"14","author":"Khurana","year":"2024","journal-title":"Blood Cancer J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26668","article-title":"Hemophagocytic lymphohistiocytosis secondary tocar\u2010t cells: update from thefda and vizient databases","volume":"97","author":"Priyadarshini","year":"2022","journal-title":"Am J Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2022.100325","article-title":"Immunotherapy in indolent non-hodgkin's lymphoma","volume":"17","author":"Amhaz","year":"2022","journal-title":"Leukemia Res Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35217","article-title":"Glofitamab as a salvage treatment for b-cell lymphomas in the real world: a multicenter study in Taiwan","volume":"130","author":"Hsu","year":"2024","journal-title":"Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285343","article-title":"New bispecific antibodies in diffuse large b-cell lymphoma","volume":"110","author":"Minson","year":"2025","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01771-6","article-title":"Multicenter real-life evaluation of the post-car prognostic index for patients with large b-cell lymphoma after car-t failure","volume":"19","author":"Farina","year":"2026","journal-title":"J Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2412869","article-title":"The landscape of t-cell engagers for the treatment of follicular lymphoma","volume":"13","author":"Rivas-Delgado","year":"2024","journal-title":"Oncoimmunology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1885982\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:45:49Z","timestamp":1783403149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1885982\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1885982"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1885982","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1885982"}}